The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC).
 
Jay Lee
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Foundation Medicine; Genentech/Roche; Lilly; Merck; Novartis; Regeneron
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; Genentech/Roche
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Novartis; Tempus AI, Inc.
Patents, Royalties, Other Intellectual Property - UCLA Patents
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Novartis
 
Brooke Rhead
Employment - Tempus
Stock and Other Ownership Interests - Johnson & Johnson/Janssen; Tempus
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; ArriVent Biopharma; AstraZeneca; Atreca; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Gilead Sciences; Hexagon; Hookipa Biotech; I-Mab; ITeos Therapeutics; LianBio; Lilly; Merck; Merus; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Sanofi; Seagan; Strata Oncology; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
Jonathan Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)
 
Maria Velez Velez
Consulting or Advisory Role - AstraZeneca
 
Arjan Gower
Consulting or Advisory Role - HMP
 
Aaron Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo Nordics; G1 Therapeutics; Gilead Sciences; IQVIA; Janssen Oncology; Jazz Pharmaceuticals; Leica Biosystems; Lilly; Molecular Axiom; MorphoSys; Novartis; Novocure; Oncocyte; Pfizer; Sanofi; Sanofi/Regeneron
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; Duality Biologics; eFFECTOR Therapeutics; WindMIL
Patents, Royalties, Other Intellectual Property - Pending Patents U.S. Provisional Patent Application No. 63/527,899
 
Paul Boutros
Consulting or Advisory Role - BioSymetrics; Intersect Diagnostics
Patents, Royalties, Other Intellectual Property - Holds patents on multiple biomarkers
 
Steven Dubinett
Stock and Other Ownership Interests - EarlyDiagnostics; LungLife AI
Consulting or Advisory Role - EarlyDiagnostics; LungLife AI
Research Funding - Janssen Research & Development
 
Edward Williams
Employment - Tempus AI, Inc.
Stock and Other Ownership Interests - Tempus AI, Inc.
Travel, Accommodations, Expenses - Tempus AI, Inc.
 
Catherine Traverso
Employment - Exact Sciences; Tempus AI, Inc
Stock and Other Ownership Interests - Exact Sciences; Tempus
 
Stamatina Fragkogianni
Employment - Tempus AI, Inc.
Stock and Other Ownership Interests - Tempus AI, Inc.
 
Michael Thompson
Employment - Aurora Health Care; Tempus AI, Inc
Stock and Other Ownership Interests - Doximity; Tempus; Tryp Therapeutics
Consulting or Advisory Role - Takeda; VIA Oncology
Patents, Royalties, Other Intellectual Property - UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle)
Other Relationship - Doximity
 
Jacob Mercer
Employment - Helsinn Therapeutics; QED Therapeutics; Tempus AI
Stock and Other Ownership Interests - Bridgebio
Travel, Accommodations, Expenses - Helsinn Therapeutics; Tempus AI
 
Amy Cummings
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Roche; Daiichi Sankyo/Lilly; Genmab; Merus; OncLive/MJH Life Sciences; Oncohost; Pfizer; Taiho Oncology; Tempus
Research Funding - Amgen Foundation; AstraZeneca (Inst); Genentech (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for bioinformatics approach to identification of motif neoepitopes